Blueprint Medicines Announces Worldwide Collaboration to Accelerate and Expand its Development of Novel Medicines in the Field of Cancer Immunotherapy
Under the terms of the agreement,
Immunokinases are intracellular targets known to regulate numerous aspects of immune response and represent an important opportunity for potentially innovative approaches to enhance the immune system's ability to recognize and eradicate tumor cells. To date, cancer immunotherapies have demonstrated important clinical benefits. However, most cancer immunotherapies have focused on antibodies or combinations with existing approved therapies and have not yet targeted immunokinases with small molecules. This collaboration seeks to develop new mechanisms of modulating the tumor immune response by targeting immunokinases with the goal of enhancing response rates and broadening the utility of using cancer immunotherapies to treat additional cancer types.
"We believe
The collaboration provides for the worldwide development and commercialization of immunokinases in the field of cancer immunotherapy for up to five small molecule drug candidates as single products or possibly in combination with
For any licensed product for which
Conference Call Information
About
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the collaboration and license agreement among
Logo - http://photos.prnewswire.com/prnh/20150605/221118LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/blueprint-medicines-announces-worldwide-collaboration-to-accelerate-and-expand-its-development-of-novel-medicines-in-the-field-of-cancer-immunotherapy-300235920.html
SOURCE
Kristin Williams, Investor Relations, Blueprint Medicines Corporation, 617-714-6674, KWilliams@blueprintmedicines.com; Dan Quinn, Media Relations, Ten Bridge Communications, Inc., 781-475-7974, dan@tenbridgecommunications.com